[ CAS No. 70315-68-3 ] {[proInfo.proName]}

Name: 70315-68-3|3-Bromo-6-nitroindazole|98%
Brand: Ambeed
SKU: A411878
Price: 9.0 USD
Availability: InStock
Rating: 98 (32 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 70315-68-3 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 70315-68-3 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 70315-68-3 ]

SDS Specification

Alternatived Products of [ 70315-68-3 ]

Product Details of [ 70315-68-3 ]

CAS No. :	70315-68-3	MDL No. :	MFCD06410881
Formula :	C₇H₄BrN₃O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	JUKJZBGTZKOXPG-UHFFFAOYSA-N
M.W :	242.03	Pubchem ID :	640613
Synonyms :

Calculated chemistry of [ 70315-68-3 ]

Physicochemical Properties

Num. heavy atoms :	13
Num. arom. heavy atoms :	9
Fraction Csp3 :	0.0
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	52.62
TPSA :	74.5 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.07 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.98
Log Po/w (XLOGP3) :	2.41
Log Po/w (WLOGP) :	2.23
Log Po/w (MLOGP) :	1.87
Log Po/w (SILICOS-IT) :	0.51
Consensus Log Po/w :	1.6

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.31
Solubility :	0.12 mg/ml ; 0.000495 mol/l
Class :	Soluble
Log S (Ali) :	-3.62
Solubility :	0.0585 mg/ml ; 0.000242 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-3.15
Solubility :	0.171 mg/ml ; 0.000708 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	2.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.09

Safety of [ 70315-68-3 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 70315-68-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 70315-68-3 ]
Downstream synthetic route of [ 70315-68-3 ]

[ 70315-68-3 ] Synthesis Path-Upstream 1~3

1
[ 7597-18-4 ]
[ 70315-68-3 ]

Reference： [1] Synthesis, 2011, # 16, p. 2651 - 2663
[2] Chemische Berichte, 1890, vol. 23, p. 3642[3] Chemische Berichte, 1892, vol. 25, p. 3152
[4] Justus Liebigs Annalen der Chemie, 1927, vol. 451, p. 285,302
[5] Patent: US2005/137243, 2005, A1, . Location in patent: Page/Page column 49
[6] Patent: US2005/277638, 2005, A1, . Location in patent: Page/Page column 50
[7] Patent: EP1380576, 2004, A1, . Location in patent: Page 62
[8] Patent: WO2014/26327, 2014, A1, . Location in patent: Page/Page column 78
[9] Patent: WO2014/28589, 2014, A2, . Location in patent: Page/Page column 98; 99

2
[ 74209-32-8 ]
[ 70315-68-3 ]

Reference： [1] Tetrahedron, 1980, vol. 36, p. 3523 - 3534

3
[ 99-55-8 ]
[ 70315-68-3 ]

Reference： [1] Chemische Berichte, 1890, vol. 23, p. 3642[2] Chemische Berichte, 1892, vol. 25, p. 3152
[3] Chemische Berichte, 1890, vol. 23, p. 3642[4] Chemische Berichte, 1892, vol. 25, p. 3152

[ 70315-68-3 ] Synthesis Path-Downstream 1~88

1
[ 70315-68-3 ]
[ 108-24-7 ]
1-acetyl-3-bromo-6-nitro-1<i>H</i>-indazole [ No CAS ]

Reference： [1]Justus Liebigs Annalen der Chemie,1927,vol. 451,p. 285,302

2
[ 70315-68-3 ]
[ 74209-41-9 ]
[ 74209-32-8 ]

Reference： [1]Journal of the Chemical Society,1941,p. 113,117

3
[ 70315-68-3 ]
[ 52347-72-5 ]

Reference： [1]Patent: US2787515,1955,
[2]European Journal of Medicinal Chemistry,2012,vol. 57,p. 240 - 249

4
[ 7597-18-4 ]
[ 70315-68-3 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 116A 3-bromo-6-nitro-1H-indazole A mixture of NaOH (2.0 g, 50 mmol) in H2O (60 mL) was added 6-nitroindazole (2.0 g, 12 mmol) and the suspension heated until a red solution formed. The mixture was placed in an ice-water bath for 15 minutes after which pyridinium tribromide (4.7 g, 15 mmol) in MeOH (15 mL) was added. The mixture was stirred at 0 C. for 5 hours after which the pH was adjusted to 7 with diluted HCl. The mixture was extracted with ethyl acetate, and the combined organic layer washed with H2O and concentrated under reduced pressure. The residue was purified by flash chromatography to provide the title compound. 1H NMR (300 MHz, DMSO-d6) delta ppm 7.84 (m, 1H), 8.02 (m, 1H), 8.50 (m, 1H), 14.16 (s, 1H); MS (DCI/NH3) m/z 243[M+H]+.
		Example 116; 2-[4-(benzyloxy)phenyl]-N-[3-bromo-1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide; Example 116A; 3-bromo-6-nitro-1H-indazole; A mixture of NaOH (2.0 g, 50 mmol) in H2O (60 mL) was added 6-nitroindazole (2.0 g, 12 mmol) and the suspension heated until a red solution formed. The mixture was placed in an ice-water bath for 15 minutes after which pyridinium tribromide (4.7 g, 15 mmol) in MeOH (15 mL) was added. The mixture was stirred at 0 C. for 5 hours after which the pH was adjusted to 7 with diluted HCl. The mixture was extracted with ethyl acetate, and the combined organic layer washed with H2O and concentrated under reduced pressure. The residue was purified by flash chromatography to provide the title compound. 1H NMR (300 MHz, DMSO-d6) delta ppm 7.84 (m, 1H), 8.02 (m, 1H), 8.50 (m, 1H), 14.16 (s, 1H); MS (DCI/NH3) m/z 243[M+H]+.
	With N-Bromosuccinimide; In DMF (N,N-dimethyl-formamide); at 20℃; for 1h;	To a solution of 5.0 g of 6-nitro-1H-indazole in 50 ml dimethylformamide was added 5.73 g of N-bromosuccinimide at room temperature, and the mixture was stirred at the same temperature for 1 hour. After removing the solvent by distillation, the residue was added with 250 ml of ethyl acetate. The mixture was sequentially washed with half-saturated aqueous sodium hydrogencarbonate solution, water and brine, and dried over anhydrous magnesium sulfate. After filtrating the organic layer through a silica gel pat, the solvent was evaporated and the resulting crystals were suspended in toluene, to give 6.59 g of the title compound as light brown crystals.1H-NMR (400 MHz, DMSO-D6) d 7.84 (1H, d, J = 8.8 Hz), 8.01 (1H, dd, J = 2.0, 8.8 Hz) , 8.50 (1H, d, J = 2.0 Hz).

	With bromine; sodium hydroxide; In tetrahydrofuran; at 20℃;	A mixture of 6-nitro-lH- indazole (H-l) (5 g, 30 mmol) and NaOH (2 M, 20 ml) in 20 ml THF, Br2 (9.5 g, 60 mmol) dissolved in NaOH (2 M, 100 ml) was added, the mixture was stirred at RT for 1 night. The solvent was evaporated, The precipitated solid was filtered, washed with water (30 ml) and n- hexane (50 ml), dried to afford an off white solid H-2. LCMS (ESI): calc'd for C7H4BrN302 [M+H] +: 242 found: 242.
	With bromine; sodium hydroxide; In tetrahydrofuran; water; at 20℃;	A mixture of 6-nitro-1H- indazole (H-i) (5 g, 30 mmol) and NaOH (2 M, 20 ml) in 20 ml THF was made, Br2 (9.5 g, 60 mmol) dissolved in NaOH (2 M, 100 ml) was added, and the mixture was stirred at room temperature for 1 night. The solvent was evaporated, and the precipitated solid was filtered, washed with water (30 ml) and n-hexane (50 ml), and dried to afford an off-white solid H-2. LCMS (ESI): calc?d for C7H4BrN3O2 [M+H] : 242 found: 242.

Reference： [1]Synthesis,2011,p. 2651 - 2663
[2]Chemische Berichte,1890,vol. 23,p. 3642
Chemische Berichte,1892,vol. 25,p. 3152
[3]Justus Liebigs Annalen der Chemie,1927,vol. 451,p. 285,302
[4]Patent: US2005/137243,2005,A1 .Location in patent: Page/Page column 49
[5]Patent: US2005/277638,2005,A1 .Location in patent: Page/Page column 50
[6]Patent: EP1380576,2004,A1 .Location in patent: Page 62
[7]Patent: WO2014/26327,2014,A1 .Location in patent: Page/Page column 78
[8]Patent: WO2014/28589,2014,A2 .Location in patent: Page/Page column 98; 99

5
[ 74209-32-8 ]
[ 70315-68-3 ]

Reference： [1]Tetrahedron,1980,vol. 36,p. 3523 - 3534

Yield	Reaction Conditions	Operation in experiment
90%	With N-Bromosuccinimide; In N,N-dimethyl-formamide; at 20℃; for 2h;	General procedure: 1H-Indazole-5-carbonitrile (90 mg, 0.62 mmol) was dissolved in dry DMF (1 mL) and N-bromosuccinimide (134 mg, 0.75 mmol) was added at room temperature and stirred at this temperature for 2 hours. After removal of the solvent under vacuum, the residue was treated with ethyl acetate, washed successively with saturated aqueous solution of sodium hydrogen carbonate, water and brine. The organic extracts were dried over anhydrous sodium sulphate and the solvent was removed under vacuum to afford the title compound (128 mg, 93%). LRMS (m/z): 222/224 (Br).
78.7%	With N-Bromosuccinimide; In acetonitrile; for 0.5h;Reflux;	General procedure: Compound 8 (0.500g, 3.07mmol), NBS (0.600g, 3.37mmol), dissolved in acetonitrile and heated to reflux for 30min, then the solvent rotary evaporated to dryness, added ethyl acetate (25mL), washed with water (50 mL) twice, the organic phase was separated and washed successively with 10% sodium thiosulfate solution, water (50mL), saturated brine, then the organic phase was separated, dried over anhydrous sodium sulfate, filtered, and the solvent was spin-dried to give the title compound. Using this method the synthesis of 10d-10e.

7
silver salt of 6-nitro-indazole [ No CAS ]
[ 70315-68-3 ]

Reference： [1]Justus Liebigs Annalen der Chemie,1927,vol. 451,p. 285,302

8
[ 70315-68-3 ]
[ 117883-42-8 ]

Reference： [1]Patent: US2787515,1955,

9
[ 99-55-8 ]
[ 70315-68-3 ]

Reference： [1]Chemische Berichte,1890,vol. 23,p. 3642
Chemische Berichte,1892,vol. 25,p. 3152
[2]Chemische Berichte,1890,vol. 23,p. 3642
Chemische Berichte,1892,vol. 25,p. 3152

10
[ 70315-68-3 ]
[ 62942-25-0 ]
3-(3-fluorophenyl)-6-nitro-1H-indazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	tetrakis(triphenylphosphine) palladium(0); In 1-methyl-pyrrolidin-2-one; at 180℃; for 2h;	To a solution of 1.0 g of <strong>[70315-68-3]3-bromo-6-nitro-1H-indazole</strong> in 10 ml N-methylpyrrolidone were added 2.0 g of (3-fluorophenyl)tri-n-butyltin, and 480 mg of tetrakis(triphenylphosphine)palladium(0), and the mixture was stirred at 180C for 2 hours. To the reaction mixture was added 60 ml of ethyl acetate. The mixture was sequentially washed with water (x2) and brine, dried over anhydrous magnesium sulfate and the solvent was evaporated. The crude product was purified and separated by silica gel column chromatography (ethyl acetate:toluene = 1:49), to give 302 mg of the title compound as orange crystals.1H-NMR (400 MHz, DMSO-D6) d 7.30 (1H, td, J = 8.8, 2.8 Hz), 7.61 (1H, td, J = 8.8, 6.4 Hz), 7.79 (1H, dd, J = 8.8, 1.6 Hz), 7.89 (1H, d, J = 7. 2 Hz), 8.02 (1H, dd, J = 8.8, 2.0 Hz), 8.36 (1H, d, J = 8.8 Hz), 8.52 (1H, d, J = 2.0 Hz), 14.08 (1H, s).

Reference： [1]Patent: EP1380576,2004,A1 .Location in patent: Page 62

11
[ 5050-41-9 ]
[ 70315-68-3 ]
[ 854923-23-2 ]

Yield	Reaction Conditions	Operation in experiment
64%	With potassium carbonate; In DMF (N,N-dimethyl-formamide); at 50℃; for 6.5h;	EXAMPLE 116B 3-bromo-6-nitro-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazole A mixture of 3-bromo-6-nitro1H-indazole (1.0 g, 4.1 mmol) and potassium carbonate (2.9 g 21 mmol) in DMF (20 mL) was stirred for 30 minutes after which 1-(2-chloro-ethyl)-pyrrolidine (1.8 g, 10 mmol) was added. The mixture was heated to 50 C. for 6 hours, cooled to room temperature and filtered through a plug of silica gel which was rinsed with triethylamine/ethyl acetate (1/4). The filtrate was concentrated under reduced pressure and purified by flash chromatography (silica gel, triethylamine/ethyl acetate 1/30) to provide the title compound (900 mg, 64%). 1H NMR (300 MHz, DMSO-d6) ppm 1.61 (m, 4H), 2.47 (m, 4H), 2.90 (t, 2H, J=6.44), 4.69 (t, J=6.44, 2H), 7.82 (n, 1H), 8.02 (m, 1H), 8.86 (m, 1H); MS (DCI/NH3) m/z 339 [M+H]+.
64%		Example 116B; 3-bromo-6-nitro-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazole; A mixture of <strong>[70315-68-3]3-bromo-6-nitro-1H-indazole</strong> (1.0 g, 4.1 mmol) and potassium carbonate (2.9 g 21 mmol) in DMF (20 mL) was stirred for 30 minutes after which 1-(2-chloro-ethyl)-pyrrolidine (1.8 g, 10 mmol) was added. The mixture was heated to 50 C. for 6 hours, cooled to room temperature and filtered through a plug of silica gel which was rinsed with triethylamine/ethyl acetate (1/4). The filtrate was concentrated under reduced pressure and purified by flash chromatography (silica gel, triethylamine/ethyl acetate 1/30) to provide the title compound (900 mg, 64%). 1H NMR (300 MHz, DMSO-d6) ppm 1.61 (m, 4H), 2.47 (m, 4H), 2.90 (t, 2H, J=6.44), 4.69 (t, J=6.44, 2H), 7.82 (m, 1H), 8.02 (m, 1H), 8.86 (m, 1H); MS (DCI/NH3) m/z 339 [M+H]+.

Reference： [1]Patent: US2005/137243,2005,A1 .Location in patent: Page/Page column 49
[2]Patent: US2005/277638,2005,A1 .Location in patent: Page/Page column 50

12
[ 110-87-2 ]
[ 70315-68-3 ]
[ 1339955-82-6 ]

Reference： [1]Synthesis,2011,p. 2651 - 2663

13
[ 70315-68-3 ]
[ 1339956-03-4 ]

Reference： [1]Synthesis,2011,p. 2651 - 2663

14
[ 70315-68-3 ]
[ 1562453-90-0 ]

Reference： [1]Patent: WO2014/26327,2014,A1
[2]Patent: WO2014/28589,2014,A2

15
[ 70315-68-3 ]
[ 1562453-93-3 ]

Reference： [1]Patent: WO2014/26327,2014,A1
[2]Patent: WO2014/28589,2014,A2

16
[ 70315-68-3 ]
[ 1562453-95-5 ]

Reference： [1]Patent: WO2014/26327,2014,A1
[2]Patent: WO2014/28589,2014,A2

17
[ 70315-68-3 ]
[ 1562450-34-3 ]

Reference： [1]Patent: WO2014/26327,2014,A1
[2]Patent: WO2014/28589,2014,A2

18
[ 70315-68-3 ]
[ 1562453-97-7 ]

Reference： [1]Patent: WO2014/26327,2014,A1
[2]Patent: WO2014/28589,2014,A2

19
[ 70315-68-3 ]
[ 1562454-02-7 ]

Reference： [1]Patent: WO2014/26327,2014,A1
[2]Patent: WO2014/28589,2014,A2

20
[ 70315-68-3 ]
[ 1562450-41-2 ]

Reference： [1]Patent: WO2014/26327,2014,A1
[2]Patent: WO2014/28589,2014,A2

21
2-chloro-6-(trifluoromethyl)benzoyl chloride [ No CAS ]
[ 70315-68-3 ]
[ 1562453-79-5 ]

Yield	Reaction Conditions	Operation in experiment
	With dmap; triethylamine; In dichloromethane; at 20℃;	To a 250 mL round-bottomed flask, was added 3-bromo- 6-nitro-lH-indazole (H-2) (9.4 g, 38.7 mmol), (2-chloro-6-(trifluoromethyl) benzoyl chloride) (10.3g, 42.6mmol), DMAP (472 mg, 3.87 mmol) and CH2C12 (lOOmL), after stirring at RT for 3 minutes, TEA (11.2 mL, 77 mmol) was added slowly. The reaction mixture is stirred at RT for overnight. LC-MS showed no starting materials remained. Then the mixture was poured to 30 mL water, the lower (organic) and upper (aqueous) phases are separated. The aqueous phase is extracted twice with 50 ml CH2C12. The combined organic phases are washed successively with two 20 ml portions of water and 10 ml of brine. The reaction resulting organic phase is dried over anhydrous sodium sulfate, filtered and concentrated at reduced pressure to give a yellow solid. The residue was purified by column chromatography (PE IE A from 50/1 to 10/1), to give a solid H-3. LCMS (ESI): calc'd for Ci5H6BrClF3N303 [M+H] +: 448, found: 448.
		To a 250 mL round-bottomed flask, was added 3-bromo- 6-nitro-1H-indazole (H-2) (9.4 g, 38.7 mmol), (2-chloro-6-(trifluoromethyl) benzoyl chloride) (10.3g, 42.6mmol), DMAP (472 mg, 3.87 mmol) and CH2C12 (lOOmL); after stirring at room temperature for 3 minutes, TEA (11.2 mL, 77 mmol) was added slowly. Thereaction mixture was stirred at room temperature overnight. LCMS showed that no starting materials remained. Then the mixture was poured into 30 mL water, and the lower (organic) and upper (aqueous) phases were separated. The aqueous phase was extracted twice with 50 ml CH2C12. The combined organic phases were washed successively with two 20 ml portions of water and 10 ml of brine. The resulting organic phase was dried over anhydrous sodiumsulfate, filtered and concentrated at reduced pressure to give a yellow solid. The residue was purified by column chromatography (PE/EA from 50/1 to 10/1), to give a solid H-3. LCMS (ESI): calc?d for C15H6BrClF3N3O3 [M+H]+: 448, found: 448.

Reference： [1]Patent: WO2014/26327,2014,A1 .Location in patent: Page/Page column 78-79
[2]Patent: WO2014/28589,2014,A2 .Location in patent: Page/Page column 98; 99

22
[ 70315-68-3 ]
6-benzyl-3-bromo-6-methyl-1,5,6,8-tetrahydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

23
[ 70315-68-3 ]
6-benzyl-3-bromo-6-methyl-7-oxo-6,7-dihydro-1H-pyrazolo[3,4-g]quinoxalin-1,5,8-tricarboxylic acid tri-tert-butyl ester [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

24
[ 70315-68-3 ]
6-benzyl-6-methyl-7-oxo-3-(pyridin-4-yl)-6,7-dihydro-1H-pyrazol[3,4-g]quinoxalin-1,5,8-tricarboxylic acid tri-tert-butyl ester [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

25
[ 70315-68-3 ]
6-benzyl-6-methyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

26
[ 70315-68-3 ]
6-benzyl-5,6-dimethyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

27
[ 70315-68-3 ]
6-benzyl-3-bromo-1,8-dihydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

28
[ 70315-68-3 ]
3-bromo-6-(1-phenylethyl)-1,8-dihydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

29
[ 70315-68-3 ]
3-bromo-7-oxo-6-(1-phenylethyl)-7,8-dihydro-1H-pyrazolo[3,4-g]quinoxalin-1-carboxylic acid tert-butyl ester [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

30
[ 70315-68-3 ]
7-carbonyl-6-(1-phenylethyl)-3-(pyridin-4-yl)-7,8-dihydro-1H-pyrazol[3,4-g]quinoxaline-1-carboxylic acid tert-butyl ester [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

31
[ 70315-68-3 ]
6-(1-phenylethyl)-3-(pyridin-4-yl)-1,8-dihydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

32
[ 70315-68-3 ]
6-(1-phenylethyl)-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazol[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

33
[ 70315-68-3 ]
5-methyl-6-((R)-1-phenylethyl)-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazol[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

34
[ 70315-68-3 ]
(E)-6-benzyliden-3-bromo-7-carbonyl-6,7-dihydro-1H-pyrazolo[3,4-g]quinoxaline-1,5,8-tricarboxylic acid tri-tert-butyl ester [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

35
[ 70315-68-3 ]
tri-tert-butyl (E)-6-benzylidene-7-oxo-3-(pyridin-4-yl)-6,7-dihydro-1H-pyrazolo[3,4-g]quinoxaline-1,5,8-tricarboxylate [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

36
[ 70315-68-3 ]
6-benzyl-3-(pyridin-4-yl)-1,8-dihydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

37
[ 70315-68-3 ]
6-benzyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

38
[ 70315-68-3 ]
6-benzyl-5-methyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

39
[ 70315-68-3 ]
6-phenylmethyl-5-neopentyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

40
[ 70315-68-3 ]
3-bromo-5,6-dinitro-1H-indazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	With sulfuric acid; potassium nitrate; at 0 - 20℃;	<strong>[70315-68-3]3-bromo-6-nitro-1H-indazole</strong> (3.0 g, 12.4 mmol) dissolved in 30 mL of concentrated sulfuric acid,Cooled to 0 C, added dropwise to a solution of potassium nitrate (1.38 g, 13.64 mmol) dissolved in concentrated sulfuric acid (30 mL). After the dropwise addition was completed, the mixture was stirred at 0 C for 30 minutes, the ice water bath was removed, and the mixture was stirred at room temperature overnight. The reaction solution was added dropwise to 360 g of ice-water mixture, and the precipitate was filtered, washed with water, and dried to give the desired product 3-bromo-5,6-dinitro-1H-indazole (3.2 g, yield 90%)

Reference： [1]Patent: CN109761986,2019,A .Location in patent: Paragraph 0192; 0195-0198

41
[ 70315-68-3 ]
6-benzyl-5-cyclopropyl-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

42
[ 70315-68-3 ]
6-benzyl-5-(2-methoxyethyl)-3-(pyridin-4-yl)-1,5,6,8-tetrahydro-7H-pyrazolo[3,4-g]quinoxalin-7-one [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

43
[ 70315-68-3 ]
(E)-6-benzyliden-3-(2-methylpyridin-4-yl)-7-carbonyl-6,7-dihydro-1H-pyrazol[3,4-g]quinoxalin-1,5,8-tricarboxylic acid tri-tert-butyl ester [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

44
[ 70315-68-3 ]
tri-tert-butyl (E)-6-benzylidene-3-(2-fluoropyridin-4-yl)-7-carbonyl-6,7-dihydro-1H-pyrazolo[3,4-g]quinoxaline-1,5,8-tricarboxylate [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

45
[ 70315-68-3 ]
3-bromo-1H-indazol-5,6-diamine [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

46
[ 70315-68-3 ]
(E)-6-benzyliden-3-(2-methoxypyridin-4-yl)-7-carbonyl-6,7-dihydro-1H-pyrazolo[3,4-g]quinoxalin-1,5,8-tricarboxylic acid tri-tert-butyl ester [ No CAS ]

Reference： [1]Patent: CN109761986,2019,A

47
[ 70315-68-3 ]
3-(2-methylpyridin-4-yl)-5,6-dinitro-1-trityl-1H-indazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

48
[ 70315-68-3 ]
3-(2-methylpyridin-4-yl)-1-trityl-1H-indazole-5,6-diamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

49
[ 70315-68-3 ]
3-(2-methylpyridin-4-yl)-6-(trichloromethyl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran 5: acetic acid / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

50
[ 70315-68-3 ]
methyl 3-(2-methylpyridin-4-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 6 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran 5: acetic acid / 20 °C 6: methanol / Reflux

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

51
[ 70315-68-3 ]
(R)-3-(2-methylpyridin-4-yl)-N-(1-phenylethyl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran 5: acetic acid / 20 °C 6: methanol / Reflux 7: 1 h / 150 °C / Microwave irradiation

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

52
[ 70315-68-3 ]
(R)-3-(2-methylpyridin-4-yl)-N-(1-phenylethyl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran 5: acetic acid / 20 °C 6: methanol / Reflux 7: 1 h / 150 °C / Microwave irradiation 8: trifluoroacetic acid / dichloromethane / 2 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

53
[ 70315-68-3 ]
3-bromo-5,6-dinitro-1-trityl-1H-indazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 2 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

54
[ 70315-68-3 ]
4-(5,6-dinitro-1-trityl-1H-indazol-3-yl)morpholine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1.1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2.1: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3.1: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; palladium diacetate / 1,4-dioxane / 0.17 h / 100 °C / Inert atmosphere; Sealed tube 3.2: 1.58 h / 20 - 100 °C / Inert atmosphere

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

55
[ 70315-68-3 ]
3-morpholino-1-trityl-1H-indazole-5,6-diamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1.1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2.1: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3.1: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; palladium diacetate / 1,4-dioxane / 0.17 h / 100 °C / Inert atmosphere; Sealed tube 3.2: 1.58 h / 20 - 100 °C / Inert atmosphere 4.1: hydrogen; palladium(II) hydroxide / tetrahydrofuran

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

56
[ 70315-68-3 ]
5,6-dinitro-3-(pyridin-4-yl)-1-trityl-1H-indazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

57
[ 70315-68-3 ]
methyl 3-morpholino-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1.1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2.1: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3.1: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; palladium diacetate / 1,4-dioxane / 0.17 h / 100 °C / Inert atmosphere; Sealed tube 3.2: 1.58 h / 20 - 100 °C / Inert atmosphere 4.1: hydrogen; palladium(II) hydroxide / tetrahydrofuran 5.1: N-ethyl-N,N-diisopropylamine / dichloromethane / 0 - 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

58
[ 70315-68-3 ]
3-(pyridin-4-yl)-1-trityl-1H-indazole-5,6-diamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

59
[ 70315-68-3 ]
3-bromo-1-trityl-1H-indazole-5,6-diamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: ammonium chloride; zinc / tetrahydrofuran / 70 °C / Inert atmosphere

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

60
[ 70315-68-3 ]
3-bromo-6-(trichloromethyl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: ammonium chloride; zinc / tetrahydrofuran / 70 °C / Inert atmosphere 4: acetic acid / water / 2.5 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

61
[ 70315-68-3 ]
methyl 3-bromo-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: ammonium chloride; zinc / tetrahydrofuran / 70 °C / Inert atmosphere 4: acetic acid / water / 2.5 h / 20 °C 5: methanol / 24 h / Reflux

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

62
[ 70315-68-3 ]
(R)-3-bromo-N-(1-phenylethyl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 6 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: ammonium chloride; zinc / tetrahydrofuran / 70 °C / Inert atmosphere 4: acetic acid / water / 2.5 h / 20 °C 5: methanol / 24 h / Reflux 6: 1 h / 140 °C / Microwave irradiation

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

63
[ 70315-68-3 ]
(R)-N-(1-phenylethyl)-3-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: ammonium chloride; zinc / tetrahydrofuran / 70 °C / Inert atmosphere 4: acetic acid / water / 2.5 h / 20 °C 5: methanol / 24 h / Reflux 6: 1 h / 140 °C / Microwave irradiation 7: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 1 h / 120 °C / Microwave irradiation; Inert atmosphere

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

64
[ 70315-68-3 ]
(R)-N-(1-phenylethyl)-3-(1,4-dioxaspiro[4.5]decan-8-yl)-1-trityl-1,7-dihydroimidazo[4. 5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: ammonium chloride; zinc / tetrahydrofuran / 70 °C / Inert atmosphere 4: acetic acid / water / 2.5 h / 20 °C 5: methanol / 24 h / Reflux 6: 1 h / 140 °C / Microwave irradiation 7: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 1 h / 120 °C / Microwave irradiation; Inert atmosphere 8: hydrogen; 10 wt% Pd(OH)2 on carbon / water; ethyl acetate / 5 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

65
[ 70315-68-3 ]
(R)-3-(4-oxocyclohexyl)-N-(1-phenylethyl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 9 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: ammonium chloride; zinc / tetrahydrofuran / 70 °C / Inert atmosphere 4: acetic acid / water / 2.5 h / 20 °C 5: methanol / 24 h / Reflux 6: 1 h / 140 °C / Microwave irradiation 7: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 1 h / 120 °C / Microwave irradiation; Inert atmosphere 8: hydrogen; 10 wt% Pd(OH)2 on carbon / water; ethyl acetate / 5 h / 20 °C 9: trifluoroacetic acid / 1 h / 20 - 50 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

66
[ 70315-68-3 ]
1-(3-bromo-1,7-dihydroimidazo[4,5-f]indazol-6-yl)-2-phenylethan-1-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 3 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: ammonium chloride; zinc / tetrahydrofuran / 0 - 20 °C 3: 1,4-dioxane / 10 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

67
[ 70315-68-3 ]
di-tert-butyl 3-bromo-6-(2-phenylacetyl)imidazo[4,5-f]indazole-1,7-dicarboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 4 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: ammonium chloride; zinc / tetrahydrofuran / 0 - 20 °C 3: 1,4-dioxane / 10 h / 20 °C 4: triethylamine; dmap / dichloromethane / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

68
[ 70315-68-3 ]
di-tert-butyl 6-(2-phenylacetyl)-3-(pyridin-4-yl)imidazo[4,5-f]indazole-1,7-dicarboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 5 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: ammonium chloride; zinc / tetrahydrofuran / 0 - 20 °C 3: 1,4-dioxane / 10 h / 20 °C 4: triethylamine; dmap / dichloromethane / 20 °C 5: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / tetrahydrofuran; water / 2 h / 90 °C / Inert atmosphere; Microwave irradiation

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

69
[ 70315-68-3 ]
2-phenyl-1-(3-(pyridin-4-yl)-1,7-dihydroimidazo[4,5-f]indazol-6-yl)ethan-1-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 6 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: ammonium chloride; zinc / tetrahydrofuran / 0 - 20 °C 3: 1,4-dioxane / 10 h / 20 °C 4: triethylamine; dmap / dichloromethane / 20 °C 5: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / tetrahydrofuran; water / 2 h / 90 °C / Inert atmosphere; Microwave irradiation 6: trifluoroacetic acid / dichloromethane / 2 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

70
[ 70315-68-3 ]
(R)-3-(pyridin-4-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

71
[ 70315-68-3 ]
(R)-3-(pyridin-4-yl)-N-(1-(3-(trifluoromethyl)phenyl)ethyl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation 8: trifluoroacetic acid / dichloromethane / 3 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

72
[ 70315-68-3 ]
(R)-N-(1-(3-bromophenyl)ethyl)-3-(pyridin-4-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 6 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: sodium hydrogencarbonate / tetrahydrofuran; water; acetonitrile / 3 h / 60 °C
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1
[2]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

73
[ 70315-68-3 ]
(R)-N-(1-(3-bromophenyl)ethyl)-3-(pyridin-4-yl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: sodium hydrogencarbonate / tetrahydrofuran; water; acetonitrile / 3 h / 60 °C 7: trifluoroacetic acid / dichloromethane / 2 h / 20 °C
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation 8: trifluoroacetic acid / dichloromethane / 2 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1
[2]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

74
[ 70315-68-3 ]
(R)-N-(1-(3-methoxyphenyl)ethyl)-3-(pyridin-4-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 6 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: sodium hydrogencarbonate / water; acetonitrile / 2 h / 60 °C / Inert atmosphere

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

75
[ 70315-68-3 ]
(R)-N-(1-(3-methoxyphenyl)ethyl)-3-(pyridin-4-yl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: sodium hydrogencarbonate / water; acetonitrile / 2 h / 60 °C / Inert atmosphere 7: trifluoroacetic acid / dichloromethane / 3 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

76
[ 70315-68-3 ]
(S)-N-(2-hydroxy-1-phenylethyl)-3-(pyridin-4-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1,4-dioxane / 3 h / 150 °C / Microwave irradiation

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

77
[ 70315-68-3 ]
(S)-N-(2-hydroxy-1-phenylethyl)-3-(pyridin-4-yl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1,4-dioxane / 3 h / 150 °C / Microwave irradiation 8: trifluoroacetic acid / dichloromethane / 3 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

78
[ 70315-68-3 ]
(R)-3-(pyridin-4-yl)-N-(1-(m-tolyl)ethyl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1-methyl-pyrrolidin-2-one / 3 h / 150 °C / Microwave irradiation 8: trifluoroacetic acid / dichloromethane / 3 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

79
[ 70315-68-3 ]
(R)-N-(1-(3-chlorophenyl)ethyl)-3-(pyridin-4-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 6 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: sodium hydrogencarbonate / water; trifluoroacetic acid / 4 h / 20 °C / Inert atmosphere

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

80
[ 70315-68-3 ]
(R)-N-(1-(3-chlorophenyl)ethyl)-3-(pyridin-4-yl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: sodium hydrogencarbonate / water; trifluoroacetic acid / 4 h / 20 °C / Inert atmosphere 7: trifluoroacetic acid / dichloromethane / 3 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

81
[ 70315-68-3 ]
(S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-3-(pyridin-4-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

82
[ 70315-68-3 ]
(S)-N-(1-(3-chlorophenyl)-2-hydroxyethyl)-3-(pyridin-4-yl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation 8: trifluoroacetic acid / dichloromethane / 3 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

83
[ 70315-68-3 ]
(S)-N-(2-hydroxy-1-(m-tolyl)ethyl)-3-(pyridin-4-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

84
[ 70315-68-3 ]
C₂₃H₂₀N₆O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation 8: trifluoroacetic acid / dichloromethane / 3 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

85
[ 70315-68-3 ]
(R)-N-(1-(3-(prop-1-en-2-yl)phenyl)ethyl)-3-(pyridin-4-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 7 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: sodium hydrogencarbonate / tetrahydrofuran; water; acetonitrile / 3 h / 60 °C 7: potassium carbonate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH₂Cl₂ / 1,4-dioxane; water / 1.5 h / 130 °C / Microwave irradiation
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation 8: potassium carbonate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH₂Cl₂ / 1,4-dioxane; water / 1.5 h / 130 °C / Microwave irradiation

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1
[2]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

86
[ 70315-68-3 ]
(R)-N-(1-(3-isopropylphenyl)ethyl)-3-(pyridin-4-yl)-1-trityl-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 8 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: sodium hydrogencarbonate / tetrahydrofuran; water; acetonitrile / 3 h / 60 °C 7: potassium carbonate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH₂Cl₂ / 1,4-dioxane; water / 1.5 h / 130 °C / Microwave irradiation 8: hydrogen; 10 wt% Pd(OH)2 on carbon / tetrahydrofuran / 16 h / 20 °C
	Multi-step reaction with 9 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation 8: potassium carbonate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH₂Cl₂ / 1,4-dioxane; water / 1.5 h / 130 °C / Microwave irradiation 9: hydrogen; 10 wt% Pd(OH)2 on carbon / tetrahydrofuran / 16 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1
[2]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

87
[ 70315-68-3 ]
(R)-N-(1-(3-isopropylphenyl)ethyl)-3-(pyridin-4-yl)-1,7-dihydroimidazo[4,5-f]indazole-6-carboxamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Multi-step reaction with 10 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: Reflux 7: 1 h / 150 °C / Microwave irradiation 8: potassium carbonate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH₂Cl₂ / 1,4-dioxane; water / 1.5 h / 130 °C / Microwave irradiation 9: hydrogen; 10 wt% Pd(OH)2 on carbon / tetrahydrofuran / 16 h / 20 °C 10: triethylsilane; trifluoroacetic acid / dichloromethane / 1 h / 20 °C
	Multi-step reaction with 9 steps 1: sulfuric acid; potassium nitrite / 0.5 h / 0 °C 2: caesium carbonate / N,N-dimethyl-formamide / 20 °C 3: (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium carbonate / 1,4-dioxane; water / 5 h / 80 °C / Inert atmosphere 4: palladium 10% on activated carbon; hydrogen / tetrahydrofuran / 20 °C 5: acetic acid / 20 °C 6: sodium hydrogencarbonate / tetrahydrofuran; water; acetonitrile / 3 h / 60 °C 7: potassium carbonate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH₂Cl₂ / 1,4-dioxane; water / 1.5 h / 130 °C / Microwave irradiation 8: hydrogen; 10 wt% Pd(OH)2 on carbon / tetrahydrofuran / 16 h / 20 °C 9: triethylsilane; trifluoroacetic acid / dichloromethane / 1 h / 20 °C

Reference： [1]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1
[2]Current Patent Assignee: HANSOH PHARMACEUTICAL GROUP CO LTD - US2020/247815, 2020, A1

88
[ 70315-68-3 ]
[ 24424-99-5 ]
tert-butyl 3-bromo-6-nitroindazole-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
48%	With dmap; triethylamine In dichloromethane at 25℃; for 12h;	8.2; 18.2 [0057] Step 2: tert-butyl 3-bromo-6-nitroindazole-1-carboxylate [0058] To a solution of 3-bromo-6-nitro-1H-indazole (500 mg, 2.07 mmol), tert-butoxycarbonyl tert-butyl carbonate (1.13 g, 5.16 mmol), TEA (522 mg, 5.16 mmol) in DCM (15 mL) was added DMAP (126 mg, 1.03 mmol). The mixture was stirred at 25 °C for 12 hours. After the reaction mixture was washed twice with 1 M HCl, washed with water and dried over MgSO4, concentrated and purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=15/1 to 5/1) to give the title compound (400 mg, 48% yield) as a white solid. 1H NMR (400 MHz, CD3Cl) d = 9.02 (s, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 1.68 (s, 9H).

Reference： [1]Current Patent Assignee: KIMBERLY-CLARK CORP; KYMERA THERAPEUTICS INC - WO2020/251974, 2020, A1 Location in patent: Paragraph 0057-0058; 00141-00142

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 70315-68-3 ]

Bromides

[ 74209-34-0 ]

3-Bromo-7-nitro-1H-indazole

Similarity: 0.92

[ 67400-25-3 ]

3-Bromo-5-nitroindazole

Similarity: 0.85

[ 40598-94-5 ]

3-Bromo-1H-indazole

Similarity: 0.81

[ 885518-46-7 ]

6-Bromo-4-nitro-1H-indazole

Similarity: 0.80

[ 885519-92-6 ]

3-Bromo-6-chloro-4-nitro-1H-indazole

Similarity: 0.79

Nitroes

[ 74209-34-0 ]

3-Bromo-7-nitro-1H-indazole

Similarity: 0.92

[ 67400-25-3 ]

3-Bromo-5-nitroindazole

Similarity: 0.85

[ 7597-18-4 ]

6-Nitro-1H-indazole

Similarity: 0.84

[ 885520-77-4 ]

4-Methyl-6-nitro-1H-indazole

Similarity: 0.81

[ 5401-94-5 ]

5-Nitro-1H-indazole

Similarity: 0.81

Related Parent Nucleus of
[ 70315-68-3 ]

Indazoles

[ 74209-34-0 ]

3-Bromo-7-nitro-1H-indazole

Similarity: 0.92

[ 67400-25-3 ]

3-Bromo-5-nitroindazole

Similarity: 0.85

[ 7597-18-4 ]

6-Nitro-1H-indazole

Similarity: 0.84

[ 885520-77-4 ]

4-Methyl-6-nitro-1H-indazole

Similarity: 0.81

[ 5401-94-5 ]

5-Nitro-1H-indazole

Similarity: 0.81

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 70315-68-3 ] {[proInfo.proName]}

Quality Control of [ 70315-68-3 ]

Related Doc. of [ 70315-68-3 ]

Product Details of [ 70315-68-3 ]

Calculated chemistry of [ 70315-68-3 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 70315-68-3 ]

Application In Synthesis of [ 70315-68-3 ]

[ 70315-68-3 ] Synthesis Path-Upstream 1~3

[ 70315-68-3 ] Synthesis Path-Downstream 1~88

Related Functional Groups of [ 70315-68-3 ]

Bromides

Nitroes

Related Parent Nucleus of [ 70315-68-3 ]

Indazoles

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 70315-68-3 ]

Related Parent Nucleus of
[ 70315-68-3 ]